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1364.e1 The Journal of Thoracic and CaBackground: Previously, we used cardiopulmonary bypass with incomplete cardiac
isolation and antegrade administration of vector for global cardiac gene delivery.
Here we present a translatable cardiac surgical procedure that allows for complete
surgical isolation of the heart in situ with retrograde (through the coronary venous
circulation) administration of both vector and endothelial permeabilizing agents to
increase myocyte transduction efficiency.
Methods: In 6 adult dogs the heart was completely isolated with tourniquets placed
around both vena cavae and cannulas and all pulmonary veins. On cardiopulmonary
bypass, the aorta and pulmonary artery were crossclamped, and the heart was
isolated. Crystalloid cardioplegia at 4°C containing 1013 particles of adenovirus
encoding LacZ and 15 g of vascular endothelial growth factor was infused
retrograde into the coronary sinus and recirculated for a total of 30 minutes. The
dogs were then weaned from cardiopulmonary bypass and allowed to recover. With
a catheter, 3 control dogs underwent retrograde infusion of the same cocktail
without cardiac isolation or cardiopulmonary bypass.
Results: -Galactosidase activities in the cardiopulmonary bypass group were
several orders of magnitude higher in both the right and left ventricles when
compared with those in the control group (P  .05). X-gal staining from the
cardiopulmonary bypass group showed unequivocal evidence of myocyte gene
expression globally in a significant proportion of cardiac myocytes. No myocyte
gene expression was observed in the control group.
Conclusion: A novel cardiac surgical technique has been developed. This approach
with cardiac isolation and retrograde delivery of vector through the coronary sinus
results in efficient myocyte transduction in an adult large animal in vivo.
More than half of the cardiovascular deaths in the United States are due toheart failure, which still carries an unacceptably high mortality.1,2 Therehas not been a single clinical trial of gene therapy for the treatment of
heart failure, although some are now being proposed.3 In contrast, there have been
several trials designed to treat patients with coronary artery disease with both
catheter-based intracoronary infusion or direct intramyocardial injection for gene
delivery.3-9
A variety of studies using both adult murine and rodent animal models and
transgenic models of heart failure have identified promising transgenes for the
treatment of heart failure.10-17 These include the -adrenoreceptor kinase c-terminus
(ARKct),10,11 the sarcoplasmic reticulum Ca2 ATPase 2a (SERCA2a),12-15 and
the pseudophosphorylated mutant of phospholamban (S16EPLN).16,17 In spite of
this progress, there has never been a convincing demonstration of transduction of the
majority of cardiac myocytes in situ in a large adult mammal. Thus we believe that
rdiovascular Surgery ● November 2005
Bridges et al Evolving Technologythe development of translational methods for efficient trans-
gene delivery in a large adult animal model is the most
important remaining obstacle in the development of effec-
tive gene therapy for heart failure.
The endothelial barrier is the proximate rate limiter for the
achievement of widespread transvascular vector-mediated
gene delivery to skeletal myocytes in situ.18 We have pre-
viously used cardiopulmonary bypass (CPB) as a means of
delivering adenovirus encoding LacZ to canine animals.19
We achieved incomplete (1-way) isolation of the heart
because the pulmonary veins were not controlled19 and no
endothelial permeabilizing agents were administered. On
the basis of our previous observations,18 we were not sur-
prised when this approach resulted in global delivery but
transduction of only a small minority of cardiac myocytes in
the heart.19
Because the capillaries lie on the venous side of the
arteriolar resistor, retrograde (eg, venous to arterial) vector
infusion should result in a higher capillary to interstitial
pressure gradient, favoring filtration of the macromolecular
assembly (vector). We and others20 hypothesized that a
retrograde (venous to arterial) infusion approach would
result in enhanced transduction efficiency. Here we present
a new cardiac surgical procedure that allows for complete
(2-way) isolation of the heart in situ. We used this unique
approach for the first time to deliver Ad.CMV.LacZ to the
heart of an adult canine mammal in situ. In contrast to
previous applications of CPB for vector-mediated gene de-
livery,19,21,22 this technique allows us to coinfuse an endo-
thelial permeabilizing agent (vascular endothelial growth
factor [VEGF]) while avoiding potentially untoward sys-
temic side effects in an attempt to limit gene expression to
the heart. The therapeutic margin of safety is thus enhanced
by minimizing the risk of collateral gene expression in the
germ line or cornea. We also compare, using quantitative
and histochemical methods, the relative transduction effi-
ciency of our novel delivery technique to a control group in
which an equal titer of vector and equal dose of VEGF are
administered retrograde directly through a catheter in the
coronary sinus. The control group simulates what could be
achieved with a percutaneous catheter–based transvascular
vector delivery technique in a large adult mammal.
Methods
Both the experimental group, (n  6, CPB group) and the control
Abbreviations and Acronyms
AAV  adeno-associated virus
CPB  cardiopulmonary bypass
VEGF vascular endothelial growth factorgroup, (n  3, catheter group) consist of normal adult male dogs,
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undergo gene delivery by a novel cardiac isolation procedure with
retrograde infusion and recirculation of vector with CPB described
below. Animals in the catheter group undergo gene delivery with
a catheter introduced into the coronary sinus without CPB and
without isolation of the heart. All animals are cared for in a
humane fashion and in compliance with the “Guide for the
Care and Use of Laboratory Animals” (www.nap.edu/catalog/
5140.html). One hour before surgical intervention, each animal is
premedicated with acepromazine (0.1 mg/kg) and glycopyrrolate
(0.001 mg/kg; INN: glycopyrronium bromide). General anesthesia
is induced with ketamine (10 mg/kg) and diazepam (0.5 mg/kg)
intravenously and maintained with inhaled oxygen and isoflurane
(1%-2%). Cefazolin (25 mg/kg intravenously) is administered
prophylactically.
CPB Group
The left femoral artery is cannulated. A median sternotomy inci-
sion is made, and the sternum is divided. Excess thymus tissue is
excised (if necessary). Aminocaproic acid (Amicar), 5 g, is ad-
ministered intravenously. All cannulas and stopcocks are pre-
flushed with albumin to avoid inactivation of adenovirus.23 Purse-
string sutures are placed around the right atrial appendage, on the
right atrium adjacent to the atrioventricular groove, and on the
right atrium near its junction with the inferior vena cava. A no. 1
silk heavy suture is doubly placed around the superior vena cava
and connected to a tourniquet. With the use of pericardial pledgets
and 4-0 Prolene sutures, a horizontal mattress pledgeted-supported
suture is placed on the ascending aorta approximately 1 cm distal
to the aortic root. The aorta and pulmonary artery are ensnared
with umbilical tapes. The pulmonary artery is ensnared by exclu-
sion. Heparin is administered (130 U/kg). The right carotid artery
is cannulated with a 12F cannula. By using the previously placed
purse-string sutures, (1) a cardioplegia cannula (containing a vent
limb) is placed in the ascending aorta, (2) the superior vena cava
is cannulated with a 26F right angle cannula, (3) a retrograde
catheter is placed into the coronary sinus, and (4) the inferior vena
cava is cannulated with a 26F right angle cannula. The 2 venous
cannulas are connected to a Y connector and connected to the
venous limb of the pump circuit. CPB is initiated. All of the
pulmonary veins are ensnared, individually or in groups, by um-
bilical tapes and tourniquets. The azygos vein is ligated. The
inferior vena cava is snared with a double loop of 0 silk sutures. A
purse-string suture is placed in the apex of the left ventricle.
Volume is left in the heart. A stab is made in the middle of the
purse string, and a cannula is placed into the left ventricular cavity
and clamped. A pledget-supported purse-string suture is placed in
the right ventricular outflow tract. A cannula is then placed into the
right ventricle and clamped, and the purse string is snared.
The cardiac circuit is constructed. Systemic cooling to 30°C is
initiated. Once the heart fibrillates, the aorta is crossclamped, and
50 mg of diphenhydramine (Benadryl), 100 mg of methylpred-
nisolone, and 300 mg of cimetidine are administered systemically
and simultaneously. Plegisol (Abbott Laboratories, Chicago, Ill;
pH adjusted with sodium bicarbonate to pH 7.4), 300 mL, at 4°C
is administered to arrest the heart. The virus solution is constituted
when bypass is initiated and consists of 1013 particles of Ad.CMV.
LacZ along with 5 g of human VEGF 121 (Pepro-tech, Rocky
d Cardiovascular Surgery ● Volume 130, Number 5 1364.e2
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in a total of 5 mL of phosphate-buffered saline. The coronary
circuit is isolated, and the heart is emptied of excess volume and
air. Flow into the now-isolated cardiac circuit is resumed and
progressively increased until the coronary sinus pressure equals 60
to 80 mm Hg (typically flow is approximately 100-150 mL/min).
Then one half of the virus solution (approximately 2.5 mL) is
injected slowly into a 50-mL volume (approximately 2.5 mL/kg
over 30 seconds at a circuit flow rate of 100 mL/min). Circulation
is stopped, and the solution is allowed to dwell for 10 minutes.
Flow is restored over 1 minute to 100 to 120 mL/min, with
coronary sinus pressure equal to 60 to 80 mm Hg, and the remain-
ing 2.5 mL of virus solution is infused, again over 30 seconds, and
recirculated for another 20 minutes. During this interval, the flow
is slowly increased to a maximum of 150 mL/min as needed to
maintain a coronary sinus pressure of 60 to 80 mm Hg. The
coronary sinus catheter is then removed, and the suture is tied. The
coronary circuit is then flushed antegrade with approximately 500
mL of a colloid solution with 100 mg of methylprednisolone, 50
mg of diphenhydramine, and 300 mg of cimetidine added. The
aortic crossclamp is removed, and flow is restored. Rewarming is
initiated. The inferior vena cava, superior vena cava, and pulmo-
nary vein snares are removed. The right ventricular and left ven-
tricular cannulas are converted to systemic vents. The aortic root
cannula is removed. Epinephrine is administered at 1 to 2 g/min.
Figure 1. Schematic diagram of the cardiac isolation c
ventricle; IVC, inferior vena cava.Lidocaine (50 mg bolus) is administered, and an infusion is begun
1364.e3 The Journal of Thoracic and Cardiovascular Surgery ● Nat 1 mg/min. An additional dose of 100 mg of methylprednisolone,
50 mg of diphenhydramine, and 300 mg of cimetidine is admin-
istered. Aminocaproic acid, 5 mg, is administered intravenously.
After approximately 5 minutes of systemic venting, the crossclamp
on the pulmonary artery is removed. The aortic cannula is re-
moved. The right ventricular cannula is removed. Once the heart is
contracting well, the left ventricular cannula is removed. Bypass is
discontinued after 30 minutes of reperfusion. Once hemodynamic
stability is achieved and the heparin is reversed, the chest is closed.
A schematic drawing of the cardiac isolation procedure appears in
Figure 1.
Catheter Group
A median sternotomy incision is made, and the sternum is divided.
A purse string is placed on the right atrium adjacent to the
atrioventricular groove. The retrograde catheter is placed into the
coronary sinus. As in the bypass group, the virus solution consists
of 1013 particles of Ad.CMV.LacZ along with 5 g of human
VEGF 121 and 10 g of human VEGF 165 in 5 mL of phosphate-
buffered saline. One half of the solution (2.5 mL) is injected over
30 seconds, with care to clear the catheter dead space (2 mL)
before starting the 30-second infusion interval. The solution is
allowed to dwell for 10 minutes. The remaining 2.5 mL of virus
solution is infused over 30 seconds (as above) and allowed to
dwell for 20 minutes. The retrograde catheter is then removed. The
t. SVC, Superior vena cava; RV, right ventricle; LV, leftircuichest is closed.
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Within approximately 4 hours after completion of the procedure,
the animals were weaned from mechanical ventilation and inotro-
pic support, and all chest tubes were removed. For animals in the
CBP and catheter groups, tissues were procured at necropsy on day
6 or 7 after death with an intravenous overdose of sodium pento-
barbital. Cryostat sections of the heart, liver, testis, diaphragm, and
other organs were incubated overnight at room temperature in
X-gal solution. -Galactosidase enzyme activity was quantified
with a chemiluminescent reporter assay system (Galacto-Light
Plus; Tropix, Inc, Bedford, Mass).
Statistical Methods
For comparisons of -galactosidase activities, a 2-sample Student
t test was performed between the 2 groups (catheter vs CPB).
Results
All animals in the catheter group and 5 of 6 animals in the
CPB group survived to euthanasia. -Galactosidase activities
in the CPB group were several orders of magnitude higher in
both the right and left ventricles when compared with those of
the control group (P  .05, Figure 2). I n contrast, -galacto-
sidase activities in the CPB group were significantly lower
in the liver but significantly higher in the diaphragm and
rectus abdominis than in the catheter group (P  .05, Table
E1). X-gal staining from the CPB group showed unequiv-
ocal evidence of myocyte gene expression globally in a
significant proportion of cardiac myocytes. No myocyte
gene expression was observed in the hearts of the catheter
group (Figure 3). Whole mount sections stained with X-gal
ventricular cardiomyocytes in the catheter group (a-e)
e left ventricular apex (a and f; 10; bar  0.250 mm),
eft ventricular anterior wall (c and h; 10; bar  0.250
0.250 mm), and right ventricular posterior wall (e and
cZ along with 15 g of vascular endothelial growthFigure 2. -Galactosidase activities in the hearts in the cardio-
pulmonary bypass (CPB) group (CPB with complete in situ car-
diac isolation, filled bars) and the catheter group (control; cath-
eter infusion without CPB and without cardiac isolation, open
bars). RLU, Relative light units; LA, left atrium; RA, right atrium;
LAD, left anterior descending coronary artery; PDA, posterior
descending coronary artery; RVOT, right ventricular outflow tract;
RVAW, right ventricular anterior wall; RVLW, right ventricular
lateral wall; VS, ventricular septum; LVA, left ventricular apex;
LVAW, left ventricular anterior wall; LVLW, left ventricular lateral
wall; LVPW, Left ventricular posterior wall.Figure 3. X-gal staining of gene transfer into left and right
and the CPB group (f-j). Depicted are photomicrographs of th
left ventricular lateral wall (b and g; 4; bar  0.250 mm), l
mm), right ventricular anterior free wall (d and i; 4; bar 
j; 4) 1 week after infusion of 1013 particles of Ad.CMV.Lad Cardiovascular Surgery ● Volume 130, Number 5 1364.e4
Evolving Technology Bridges et aldemonstrate transmural LacZ expression that is most pro-
nounced in the left ventricle in the CPB group. There was no
evidence of gene expression in the catheter group (Fig-
ure 4).
Discussion
Gene therapy for heart failure is an exciting yet immature
field of investigation. For the recessively inherited cardio-
myopathies, such as those associated with the sarcoglycan
deficiencies,24 X-linked cardiomyopathy,25 or the cardio-
Figure 4. X-gal staining of whole mounts of short-axis cross-
sections of hearts derived from the catheter group (a) and the CPB
group (b). Both panels a and b represent sections obtained at 1
week after vector delivery.myopathy associated with Becker’s muscular dystrophy,26
1364.e5 The Journal of Thoracic and Cardiovascular Surgery ● Noptimal therapy will almost certainly require expression of
the missing or dysfunctional gene to correct the heart failure
phenotype. For gene therapy to be optimally effective, ex-
pression of an appropriate transgene will be required in a
substantial percentage of cardiomyocytes. Unlike gene ther-
apy for coronary artery disease, in which an important goal
has been induction of collateral blood vessel formation
where short-term gene expression might be sufficient or
even desirable, optimal gene therapy for heart failure will
likely require expression of the transgene in a significant
percentage of cardiac myocytes in the long term.
In this regard, Gregorevic and associates27 have demon-
strated that adeno-associated virus (AAV) pseudotype 6
encoding LacZ transduced the majority of striated myo-
cytes, including the diaphragm, heart, and limb muscles,
after a single intravenous injection in adult mice and adult
hamsters. However, by using this approach, doses of vector
required in human subjects (approximately 1016-1017 vector
genomes) would likely be prohibitive. In contrast, our gene
delivery method allows for a higher concentration (approx-
imately 100) of vector to be delivered to the target organ
(heart) than would be achieved with a systemic intravenous
injection. As a result, the finding of AAV pseudotypes that
appear to have the ability to bypass the endothelial barrier to
a greater extent than previously appreciated is likely to
increase the therapeutic efficacy when used in conjunction
with the complete 2-way cardiac isolation delivery tech-
nique presented.
The basement membrane is an important component of
the endothelial barrier, presenting both electrostatic and
steric restriction to the transcapillary passage of macromo-
lecular complexes.28 We were fascinated by the observation
that there is a marked increase in the thickness of the
microvascular basal lamina as a function of postural hydro-
static pressure.29 These observations might provide a hy-
pothesis to explain why vector-mediated transvascular gene
delivery to striated muscle has previously been far more
successful in mice and rodents than in large animals.
In this study we have shown, for the first time, a con-
vincing and unequivocal demonstration of transgene expres-
sion in a significant percentage of cardiac myocytes in the
heart of a large adult mammal in situ using a transvascular
route of delivery with an adenoviral vector. Furthermore,
the study demonstrates that equivalent results could not be
achieved with a simple retrograde catheter infusion tech-
nique. Complete surgical isolation of the heart in situ, using
CPB with retrograde coronary sinus infusion and recircula-
tion of vector through the heart, results in an increase of
several orders of magnitude in -galactosidase activities in
the heart, significantly lower -galactosidase activities in
the liver, and no histochemical evidence of transgene ex-
pression in the liver. In each of the key comparisons, the
differences between the CPB group and the catheter group
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histochemical findings are equally striking. We did notice
higher -galactosidase activities in the diaphragm, rectus
abdominis, and lung in the CPB group than in the catheter
group. This observation most likely represents the higher
concentrations of vector achieved in the heart in the CPB
group and the effects of small collateral arteries between the
heart and the lungs, diaphragm, and chest wall.
One limitation of this approach is that gene expression is
most evident in the left ventricle and less convincingly
demonstrated in the right ventricle and ventricular septum.
Our hypothesis is that this distribution of gene expression is
due to the fact that the right ventricular and septal venous
effluent drains into the proximal portion of the coronary
sinus (ie, proximal to the position of the coronary sinus
catheter balloon). In direct analogy to our findings, it is well
recognized that retrograde cardioplegia administration pro-
vides inadequate delivery to the right ventricle.30 We are
addressing this limitation by developing new retrograde
catheters (Bridges and associates, inventors, US patent
pending) designed to allow for global retrograde delivery.
Another limitation of this technique is that CPB is required.
Furthermore, we use an infusion pressure of up to 80 mm
Hg, nearly twice the 40 mm Hg limit typically used clini-
cally. However, it is not uncommon to use simultaneous
(antegrade-retrograde) cardioplegia delivery in which sub-
stantially higher retrograde pressures might be achieved
without apparent myocardial injury. Furthermore, we did
not find clinical or histologic evidence of significant myo-
cardial toxicity or inflammatory changes using this tech-
nique. Adenovirus, although useful for these short-term
experiments, would need to be replaced with a vector, such
as AAV, to achieve the long-term gene expression neces-
sary for heart failure gene therapy.
We believe that appropriate modifications of the proce-
dures used here, using therapeutic transgenes and an AAV
delivery vector, might theoretically be added as an adjunct
to valve repair or replacement surgery, coronary artery
bypass graft surgery, or ventricular assist device implanta-
tion procedures in selected patients with heart failure. In
younger patients with known X-linked or autosomal reces-
sive cardiomyopathy, this approach might be used as pri-
mary therapy, ideally before cardiac function had deterio-
rated significantly.
In summary, CPB with complete surgical isolation of the
heart is one potential approach to solving the problem of
efficient global transvascular vector-mediated transgene de-
livery to striated muscle in the heart, currently the rate-
limiting problem in the development of effective strategies
for gene therapy for heart failure. Furthermore, this ap-
proach might also have merit in the delivery of angiogenic
transgenes to the myocardium to treat coronary ischemia,
particularly in situations in which global delivery is desir-
The Journal of Thoracic anable. In these situations gene delivery to ischemic areas
could be accomplished efficiently by using the retrograde
approach presented. In appropriate patients these methods
might one day allow molecular cardiac surgery to provide a
viable alternative to the artificial heart or cardiac trans-
plantation.
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Bridges et al Evolving TechnologyTABLE E1. Noncardiac tissue -galactosidase activities
Tissue
CPB group, RLU/g protein
(with cardiac isolation)
Catheter group RLU/g protein
(without cardiac isolation) P value
Left lung 3794 2755 48 4 .203
Right lung 10,225 9192 32 10 .283
Diaphragm* 2776 933 157  76 .035
Rectus abdominis* 616 180 50  29 .024
Right liver* 4 2 30  14 .014
Left liver* 4 1 25  2 .000
Spleen 11 6 425  498 .416
Gastric wall 257 130 175 25 .523
Testis 67 20 118 53 .362
Rectus femoris 137 50 43  3 .104
Tibialis anterior 167 87 50  18 .211
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